Literature DB >> 24329796

Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.

Nicoletta Cieri1, Sara Mastaglio, Giacomo Oliveira, Monica Casucci, Attilio Bondanza, Chiara Bonini.   

Abstract

Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CAR; TCR; adoptive cellular immunotherapy; allogeneic hematopoietic stem cell transplantation; gene therapy; suicide gene

Mesh：

Substances：

Year:  2014        PMID： 24329796     DOI： 10.1111/imr.12130

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


  25 in total

Review 1.  Retroviral vectors: from cancer viruses to therapeutic tools.

Authors:  A Dusty Miller
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

2.  Haploidentical HSCT: a 15-year experience at San Raffaele.

Authors:  C Bonini; J Peccatori; M T L Stanghellini; L Vago; A Bondanza; N Cieri; R Greco; M Bernardi; C Corti; G Oliveira; E Zappone; C Traversari; C Bordignon; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

Authors:  S Maury; M Rosenzwajg; R Redjoul; A Marcais; A Xhaard; M Cherai; L Cabanne; G Churlaud; F Suarez; G Socié; L Gregoire; K Debbache; C Bernard; J-L Beaumont; N Azar; O Boyer; F Roudot-Thoraval; J L Cohen; C Cordonnier; F M Lemoine; D Klatzmann
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

Review 4.  Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

Authors:  Kenzaburo Tani
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

5.  Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Authors:  David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 6.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.

Authors:  Ornellie Bernadin; Fouzia Amirache; Anais Girard-Gagnepain; Ranjita Devi Moirangthem; Camille Lévy; Kuiying Ma; Caroline Costa; Didier Nègre; Christian Reimann; David Fenard; Agata Cieslak; Vahid Asnafi; Hanem Sadek; Rana Mhaidly; Marina Cavazzana; Chantal Lagresle-Peyrou; François-Loïc Cosset; Isabelle André; Els Verhoeyen
Journal:  Blood Adv       Date:  2019-02-12

8.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Authors:  K Roellecke; E L Virts; R Einholz; K Z Edson; B Altvater; C Rossig; D von Laer; K Scheckenbach; M Wagenmann; D Reinhardt; C M Kramm; A E Rettie; C Wiek; H Hanenberg
Journal:  Gene Ther       Date:  2016-05-19       Impact factor: 5.250

10.  Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Authors:  A Pato; G Eisenberg; A Machlenkin; A Margalit; G Cafri; S Frankenburg; S Merims; T Peretz; M Lotem; G Gross
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.